nuclear receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
== Composition == The military was mostly composed of white South Africans, who alone were subject to conscription. The permanent force of the Army was 85% Afrikaans speaking. However, black South Africans were the second largest group, and Asians and Coloured citizens with mixed ancestry were eligible to serve as volunteers, several attaining commissioned rank. From 1971 onwards, several black battalions were raised in the Infantry and Service Corps on a tribal basis, most black soldiers serving in these exclusive tribal battalions, which had black NCOs but white commissioned officers. The first black personnel were accepted into commissioned ranks only from 1986, and then only for serving black soldiers and NCOs. The regular Commission would not be open for Bantus until 1991, and then again they would serve only in black units or Support/Service Support units, to avoid having position of authority over white combat arms personnel. The first black officer to be promoted to lieutenant colonel rank and have command over a battalion sized unit was appointed in February 1994. However, black officer candidates from the various Homeland Forces and from South West Africa/SWATF had been accepted since 1981. Units such as the 32 Battalion incorporated many black volunteers, as did the 101 Battalion. Conscription was opposed by organisations such as the End Conscription Campaign, but overall, white morale remained high—as indicated by the few recruits tried for serious disciplinary offences.
Mild glutathione synthetase deficiency usually results in the destruction of red blood cells (hemolytic anemia). Rarely, affected people also excrete large amounts of a compound called 5-oxoproline (also called pyroglutamic acid, or pyroglutamate) in their urine (5-oxoprolinuria). This compound builds up when glutathione is not processed correctly in cells. Individuals with moderate glutathione synthetase deficiency may experience symptoms beginning shortly after birth including hemolytic anemia, 5-oxoprolinuria, and elevated acidity in the blood and tissues (metabolic acidosis). In addition to the features present in moderate glutathione synthetase deficiency, individuals affected by the severe form of this disorder may experience neurological symptoms. These problems may include seizures; a generalized slowing down of physical reactions, movements, and speech (psychomotor retardation); intellectual disability; and a loss of coordination (ataxia). Some people with severe glutathione synthetase deficiency also develop recurrent bacterial infections.
==== MeSH E05.300.510 – infusions, parenteral ==== MeSH E05.300.510.520 – infusions, intra-arterial MeSH E05.300.510.555 – infusions, intralesional MeSH E05.300.510.560 – infusions, intraosseous MeSH E05.300.510.590 – infusions, intravenous
Vancomycin is recommended to be administered in a dilute solution slowly, over at least 60 min (maximum rate of 10 mg/min for doses >500 mg) due to the high incidence of pain and thrombophlebitis and to avoid an infusion reaction known as vancomycin flushing reaction. This phenomenon has been often clinically referred to as "red man syndrome". The reaction usually appears within 4 to 10 min after the commencement or soon after the completion of an infusion and is characterized by flushing and/or an erythematous rash that affects the face, neck, and upper torso, attributed to the release of histamine from mast cells. This reaction is caused by the interaction of vancomycin with MRGPRX2, a GPCR-mediating IgE-independent mast cell degranulation. Less frequently, hypotension and angioedema occur. Symptoms may be treated or prevented with antihistamines, including diphenhydramine, and are less likely to occur with slow infusion.
=== Role of MMPs in disease === When MMPs are dysregulated, they can make diseases become more aggressive and worsen them instead of curing them. For instance, elevated levels of MMP-1 releases growth factors that enhance cancer metastasis, and in diabetic foot ulcers it slows healing by over-degrading tissues. MMP-8 levels rise in asthma, and in diabetes, it increases the chronic inflammation. MMP-13 drives joint damage in osteoarthritis, while MMP-2 and MMP-9 levels soar in colorectal cancer and heart diseases, carrying out abnormal changes in vessel walls and causing fibrosis. MMP-3 aids rheumatoid arthritis and spine issues, MMP-10 affects bone growth, MMP-7 increases in artery-clogging atherosclerosis, and MMP-12 cause immune cells to overreact, causing severe inflammation. Basically, unchecked MMP activity turns helpful tools into troublemakers.
Sources: en.wikipedia.org
Barker taped his final episode on June 6, 2007, with the show airing twice on June 15; once in Daytime and once on Primetime. On October 15, 2007, Drew Carey took over hosting duties on the show. After his retirement, Barker made three return appearances to The Price is Right. He first appeared on the episode that aired on April 16, 2009, to promote his new autobiography, Priceless Memories. Barker appeared in the Showcase round at the end of the show. Barker made another guest appearance on the show to celebrate his 90th birthday, which aired on December 12, 2013. Barker announced a contestant for the first time ever on the show, along with one showcase. Barker's last appearance was a surprise appearance on April 1, 2015, for an April Fools' Day switch where he took Carey's place at the show's intro. Barker hosted the first bid and pricing game of that day before handing the hosting duties back to Carey; Barker later appeared during the showcase.
== Function == The main purpose of chondronectin is to allow chondrocytes and collagen II substrates to bond together. When bound, if forms a complex structure called an extracellular scaffold, which helps support the surrounding cells because of bioactive molecule diversity, which allows for chondrocytes to be anchored, mechanical forces to be bared, and maintaining physiological homeostasis. In order for chondronectin to be able to assist in binding within this complex as efficiently as possible, they must interact with a cartilage proteoglycan monomer. If there is a inhibitor that prevents synthesis of endogenous proteoglycans, along with beta-xylosides, it fully prevents chondrocytes from attaching via chondronectins. When cartilage cells attach chondronectin help keep the cells positioned close to important collagen and proteoglycan materials within the extracellular matrix. This allows the cells to support the framework by maintaining surrounding cartilage components. Without attachment, chondrocytes become less effective at preserving the tissue around them. Chondronectin keeps the cartilage framework strong enough to handle daily joint pressure. It helps cartilage deal with the stress caused by regular movement and compression. Since joints face constant wear, cell bonds must stay stable to help prevent tissue damage. This protein plays a key role in keeping cartilage durable and properly supported. Studies indicate that weak adhesive interaction inside cartilage matrix can gradually reduce the integrity to cartilage.
=== Research limitations === Inconsistencies in dosing, purity, and concomitant drug use makes evaluating the effects of mitragynine in humans difficult. Conversely, animal studies control for such variability, but offer limited translatable information relevant to humans. Experimental limitations aside, mitragynine has been found to interact with a variety of receptors, although the nature and extent of receptor interactions has yet to be fully characterized. Additionally, the toxicity of mitragynine and associated kratom alkaloids has yet to be fully determined in humans, nor has the risk of overdose. More studies are necessary to assess safety and potential therapeutic utility.
== Adverse events == Rare but serious adverse events reported following Proquad vaccination include allergic reactions, including swelling of the lips, tongue, or face; difficulty breathing or closing of the throat; hives; paleness; weakness; dizziness; a fast heartbeat; deafness; long-term seizures, coma, or lowered consciousness; seizures (jerking or staring) caused by fever; or temporary low platelet count. For children aged two and younger, the MMRV vaccine is associated with significantly more adverse events compared to separate administration of MMR and varicella vaccinations on the same day. There are 4.3 additional febrile seizures per 10,000 vaccinated children (95% CI 2.6–5.6), 7.5 additional mostly mild fever episodes per 100 vaccinated children (95% CI, 5.4–9.4) and 1.1 additional measles-like rash per 100 children (95% CI, 0.2–1.8). Febrile seizures caused by the MMRV vaccine occur 7 to 10 days after vaccination. In children age 4–6, there is no evidence for an increased risk in febrile seizures after the administration of Proquad compared to the separate administration of MMR and Varicella vaccines.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.